•
What is Pega and why you should learn it in 2024?
Talks about Java, Pega and Pegasystems
PD
Peter Dudek
Board Member at Insamo
Cambridge, Massachusetts
Overview
Peter Dudek is the President & Managing Partner at MRL Ventures Fund at Merck, with a focus on investing in biotech companies in Boston/New England. He has successfully invested in companies like Carisma Therapeutics and Mozart Therapeutics, contributing to their growth and success in securing funding rounds.
With a strong background in biotechnology and venture capital, Peter Dudek's leadership has been instrumental in guiding various companies as a Board Director or Observer, including Tallac Therapeutics and Caraway Therapeutics, showcasing his expertise in strategic decision-making and fostering innovation in the life sciences industry.
Work Experience
President & Managing Partner, MRL Ventures Fund
2021 - Current
Partner, MRL Ventures Fund
2018 - 2021
Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.
Raised $5,586,000.00 from Private Capital Advisors.
Board Observer
2024
Board Director
2024
Board Observer
2024
Board Director
2022
Board Observer
2021
Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein modifications.
Raised $75,000,000.00 from Longwood Fund, MRL Ventures Fund, 8VC, Omega Funds, MPM Capital, Mass General Brigham Ventures, Eli Lilly & Company Foundation, Heritage Medical Systems, Arkin Bio Ventures and Ono Venture Investment.
Board Director
2021
Tallac Therapeutics offers next generation immunotherapies for cancer patients.
Raised $88,175,000.00 from Horizon Technology Finance.
Board Director
2020
Mozart is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases.
Raised $80,000,000.00 from Ono Venture Investment, UPMC Enterprises, Pfizer Venture Investments, AbbVie, ARCH Venture Partners, Leaps by Bayer, Alexandria Venture Investments, Eli Lilly, MRL Ventures Fund and Sofinnova Partners.
Board Director
2020
AmbAgon Therapeutics is a developer of cancer molecule therapeutics.
Raised $147,999,996.00 from Mission BioCapital, RA Capital Management, Surveyor Capital, MRL Ventures Fund, Inkef, Droia Ventures, AbbVie and Nextech Invest.
Board Director
2021 - 2023
Acquired by Merck.
Rheostat Therapeutics is a bio therapeutics company.
Raised $23,000,000.00 from Michael J. Fox Foundation.
Education
Doctor of Philosophy
2000 - 2006
Bachelor of Science (Hons)
1998 - 2000
Associate of Science
1996 - 1998